FineMark National Bank & Trust Has $516,000 Position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

FineMark National Bank & Trust lowered its position in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 11.2% during the second quarter, according to its most recent 13F filing with the SEC. The firm owned 4,018 shares of the medical equipment provider’s stock after selling 505 shares during the period. FineMark National Bank & Trust’s holdings in Zimmer Biomet Holdings were worth $516,000 at the end of the most recent quarter.

Other institutional investors have also recently made changes to their positions in the company. MARSHALL WACE ASIA Ltd bought a new position in Zimmer Biomet Holdings during the first quarter valued at about $38,621,000. Cibc World Markets Corp raised its position in Zimmer Biomet Holdings by 52.9% in the first quarter. Cibc World Markets Corp now owns 21,007 shares of the medical equipment provider’s stock valued at $2,565,000 after buying an additional 7,269 shares during the last quarter. Caxton Associates LP bought a new position in Zimmer Biomet Holdings during the first quarter valued at about $403,000. Bank of Nova Scotia raised its position in Zimmer Biomet Holdings by 933.9% in the first quarter. Bank of Nova Scotia now owns 45,996 shares of the medical equipment provider’s stock valued at $5,616,000 after buying an additional 41,547 shares during the last quarter. Finally, Koch Industries Inc. bought a new position in Zimmer Biomet Holdings during the first quarter valued at about $255,000. 82.84% of the stock is currently owned by institutional investors.

Shares of Zimmer Biomet Holdings, Inc. (ZBH) opened at 111.38 on Friday. The stock has a market cap of $22.52 billion, a price-to-earnings ratio of 31.72 and a beta of 1.20. The firm has a 50-day moving average price of $122.63 and a 200-day moving average price of $121.15. Zimmer Biomet Holdings, Inc. has a 12 month low of $95.63 and a 12 month high of $133.49.

Zimmer Biomet Holdings (NYSE:ZBH) last posted its quarterly earnings results on Thursday, July 27th. The medical equipment provider reported $2.08 earnings per share for the quarter, missing the Zacks’ consensus estimate of $2.10 by $0.02. The company had revenue of $1.95 billion for the quarter, compared to analysts’ expectations of $1.95 billion. Zimmer Biomet Holdings had a return on equity of 16.70% and a net margin of 9.12%. The business’s revenue for the quarter was up 1.1% on a year-over-year basis. During the same period in the prior year, the business earned $2.02 EPS. Equities analysts expect that Zimmer Biomet Holdings, Inc. will post $8.24 EPS for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Friday, October 27th. Stockholders of record on Friday, September 22nd will be paid a $0.24 dividend. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.86%. The ex-dividend date is Thursday, September 21st. Zimmer Biomet Holdings’s dividend payout ratio is presently 27.59%.

WARNING: “FineMark National Bank & Trust Has $516,000 Position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)” was reported by BNB Daily and is the sole property of of BNB Daily. If you are reading this article on another publication, it was illegally stolen and republished in violation of US & international trademark and copyright law. The correct version of this article can be viewed at https://www.baseball-news-blog.com/2017/08/19/zimmer-biomet-holdings-inc-nysezbh-shares-sold-by-finemark-national-bank-trust-updated-updated.html.

Several equities analysts recently issued reports on ZBH shares. Goldman Sachs Group, Inc. (The) assumed coverage on Zimmer Biomet Holdings in a research report on Tuesday, May 16th. They set a “sell” rating and a $92.00 price target on the stock. Canaccord Genuity reiterated a “buy” rating on shares of Zimmer Biomet Holdings in a research note on Friday, April 28th. Zacks Investment Research cut Zimmer Biomet Holdings from a “hold” rating to a “strong sell” rating in a research note on Tuesday, August 8th. Wells Fargo & Company lowered Zimmer Biomet Holdings from an “outperform” rating to a “market perform” rating in a report on Friday, April 28th. Finally, Morgan Stanley boosted their price target on Zimmer Biomet Holdings from $137.00 to $150.00 and gave the company an “overweight” rating in a report on Monday, July 17th. Four equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the company. Zimmer Biomet Holdings presently has an average rating of “Hold” and a consensus price target of $136.90.

In other Zimmer Biomet Holdings news, insider Sang Yi sold 17,731 shares of the business’s stock in a transaction dated Monday, June 12th. The shares were sold at an average price of $124.56, for a total transaction of $2,208,573.36. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, VP Tony W. Collins sold 16,986 shares of the business’s stock in a transaction that occurred on Monday, July 31st. The stock was sold at an average price of $121.74, for a total transaction of $2,067,875.64. The disclosure for this sale can be found here. Insiders own 1.07% of the company’s stock.

About Zimmer Biomet Holdings

Zimmer Biomet Holdings, Inc is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products.

Institutional Ownership by Quarter for Zimmer Biomet Holdings (NYSE:ZBH)

Receive News & Ratings for Zimmer Biomet Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet Holdings Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply